title: Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
authors.forename: J
authors.initials: J
authors.lastname: Winkler
authors.forename: D
authors.initials: D
authors.lastname: Rech
authors.forename: S
authors.initials: S
authors.lastname: Kallert
authors.forename: J
authors.initials: J
authors.lastname: Rech
authors.forename: N
authors.initials: N
authors.lastname: Meidenbauer
authors.forename: W
authors.initials: W
authors.lastname: Roesler
authors.forename: A
authors.initials: A
authors.lastname: Mackensen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates; D005260:Female; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines; D012008:Recurrence; D000077157:Sorafenib; D014184:Transplantation, Homologous; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3